<DOC>
	<DOC>NCT00386334</DOC>
	<brief_summary>To evaluate the long-term safety and efficacy of eszopiclone administered for 12 weeks in elderly subjects with primary chronic insomnia.Administration of eszopiclone 2 mg daily at bedtime for 12 weeks in elderly subjects with a diagnosis of primary chronic insomnia will be safe and well tolerated, improve subjective sleep measures, improve measures of Quality of Life and next day insomnia symptoms, and have no significant withdrawal central nervous system adverse events or rebound insomnia.</brief_summary>
	<brief_title>A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia</brief_title>
	<detailed_description>A double-blind, randomized, placebo controlled, parallel group study of eszopiclone in elderly subjects with primary chronic insomnia. The study will involve up to 9 visits and subject participation will be approximately 18 weeks. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.</detailed_description>
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Male and female subjects with primary chronic insomnia. Subject is otherwise in good general health, based on screening physical examination and medical history. Subject has recent history of known clinically significant abnormal laboratory findings.</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>insomnia</keyword>
	<keyword>chronic</keyword>
	<keyword>primary</keyword>
</DOC>